Experimental/treatment arm for Pulmonary Fibrosis

Phase-Based Progress Estimates
Kit Bartalos, Liberty, MO
Pulmonary Fibrosis+4 More
EV-Pure™ and WJ-Pure™ plus standard care - Drug
All Sexes
What conditions do you have?

Study Summary

The COVID-induced fibrotic lung damage continues long after viral infection has subsided and is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance of developing a persistent respiratory system pathology and a 10% chance of developing a severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration, reduction of exercise tolerance, and concomitant development of persistent fibrotic lung damage. This study intends to evaluate benefits of a combination of WJPure and EVPure in Covid-19 patients exhibiting pulmonary fibrosis.

Eligible Conditions

  • Pulmonary Fibrosis
  • COVID-19 Respiratory Infection

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: 3 months

3 months
Change in Pulse Oximetry at Rest and During the 6MWT
Evaluate incidences of Treatment-Emergent Adverse Events following following EV-Pure™ and WJ-Pure™ administeration to patients exhibiting Covid induced Pulmonary Fibrosis.
Incidence of Re-Hospitalization
Quality of Life assessment as collected using the SF-36
To evaluate the efficacy of EV-Pure™ and WJ-Pure™ administration in alleviating long term symptoms of Covid induced Pulmonary Fibrosis, compared to placebo

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Experimental/treatment arm
1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

20 Total Participants · 2 Treatment Groups

Primary Treatment: Experimental/treatment arm · Has Placebo Group · Phase 1

Experimental/treatment arm
Experimental Group · 1 Intervention: EV-Pure™ and WJ-Pure™ plus standard care · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months
Closest Location: Kit Bartalos · Liberty, MO
N/AFirst Recorded Clinical Trial
1 TrialsResearching Pulmonary Fibrosis
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a confirmed and documented COVID-19 infection history with a confirmed diagnosis of Pulmonary Fibrosis.
You have no current or recent (within the last 14 days) infection with the coronavirus.
You have normal blood and liver and kidney functions.
You have adequate renal function as evidenced by a serum creatinine ≤ 1.5 X ULN for the reference laboratory OR a calculated creatinine clearance of ≥ 60 mL/min by the Cockcroft-Gault Equation.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.